Regenerative therapy is the process of replacing or "regenerating" human cells, tissues or organs to restore or establish normal function. It replaces damaged tissue or stimulates the body's own repair mechanisms to heal tissues or organs, thereby regenerating damaged tissues and organs in the body.

The global regenerative therapies market is estimated to account for US$ 10,421.5 Mn in terms of value in 2019 and is expected to reach US$ 45,940.7 Mn by the end of 2027.

Global Regenerative Therapies Market: Drivers

Rapid growth of stem cell businesses is expected to propel growth of the global regenerative therapies market over the forecast period. For instance, according to the study, “The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions”, published in the journal Perspectives in Biology and Medicine, in 2018, the number of new stem cell businesses with websites doubled on average every year between 2009 and 2014, in the U.S.

Global Regenerative Therapies Market: Opportunities 

Increasing prevalence of neurological disorders is expected to offer lucrative growth opportunities for players in the market. For instance, according to the study, “Prevalence of Parkinson’s disease (PD) across North America”, published in July 2018 in the journal Nature, the number of people suffering from PD is expected to reach 930,000 in 2020 and 1,238,000 in 2030.

Global Regenerative Therapies Market: Restraints

Lack of financial-backing of smaller firms is expected to hinder growth of the global regenerative therapies market. A common trait in the regenerative therapies industry is the unavailability of proper financing options for smaller organizations. This is one of the main factors hampering R&D in the field of regenerative therapies. Quite observed in resource-poor settings, many promising targets have been abandoned half way during clinical trial phase due to lack of financing support stemming from insufficient data on proven efficacy. Furthermore, emergence and growth of start-ups researching on and producing regenerative therapies has been hampered by lack of lucrative co-marketing collaborations from medical devices companies (especially in orthopedics – the largest application segment in terms of revenue generation) and in-licensing and out-licensing deals.

Key Takeaways:

Allograft held dominant position in the global regenerative therapies market in 2019, accounting for 57.7% share in terms of value, followed by xenograft and alloplast, respectively. Allograft is a biological regenerative material which is transplanted from one person to other i.e. from a donor to receiver. Increasing applications is expected to support growth of the segment.

Orthopedic segment held dominant position in the global regenerative therapies market in 2019, accounting for 37.2% share in terms of value, followed by soft tissue repair, and cardiovascular, respectively. Rampant research activities and rapid development of innovative products by key players is expected to support growth of the segment. For instance, in 2015, NuVasive Inc.—U.S.-based company—launched its new innovative biologics technology, AttraX Putty, which is a synthetic bone graft, indicated in posterolateral spinal surgery as an autograft extender.

Hospitals segment held dominant position in the global regenerative therapies market in 2019, accounting for 84.3% share in terms of value, followed by ambulatory surgical centers and educational institutes, respectively.

Market Trends

Major players in the market are focused on developing novel platforms biological therapeutic products to expand their product portfolio. For instance, in March 2020, Pluristem Therapeutics Inc., a regenerative medicine company, announced that it has dosed three patients in two different hospitals in Israel under a compassionate use program for the treatment of COVID-19.

Major players in the market are also focused on expanding their capabilities. For instance, in March 2020, BioStem Life Sciences, a subsidiary of BioStem Technologies Inc. and a developer of regenerative therapies, announced to add R&D laboratory to its Florida, U.S. facility.

Regulations

Europe

The translational pipeline from basic research to the delivery of innovative stem cell-based therapies is covered by a variety of European legal instruments,  ranging from regulations on marketing authorization (Regulation (EC) no. 1394/2007) to Directives about clinical trials (Directive 2001/20/EC) and guidelines of good clinical practice (Directive 2001/83/EC, Directive 2009/120/EC).

Global Regenerative Therapies Market: Competitive Landscape  

Major players operating in the global regenerative therapies market include, Shire Pharmaceuticals, Kinetic Concepts, Inc., Mesoblast Ltd., Nuo Therapeutics (Cytomedix Inc.), Advanced Cell Technology, Inc., BioStem Life Sciences, Akron Biotechnology, LLC, Organovo Holdings Inc., Orgenesis Inc., Pluristem Therapeutics Inc., Genzyme, Athersys, Inc., RenovaCare, Inc., and Cytori Therapeutics, Inc.

Global Regenerative Therapies Market: Competitive Landscape  

March 2020: BioStem Life Sciences received its ISBT 128 Registration from the International Council for Commonality in Blood Banking Automation

February 2019: Pluristem Therapeutics Inc. collaborated with NASA’s Ames Research Center to evaluate the potential of its PLX cell therapies in preventing and treating medical conditions caused during space missions

Segmentation

  • By Tissue Type
    • Allograft
    • Xenograft
    • Alloplast
  • By Application
    • Soft Tissue Repair
    • Cardiovascular
    • Dental
    • Orthopedic
    • CNS disease treatment
    • Others
  • By End User
    • Hospitals
    • Ambulatory Surgical Centers
    • Educational Institutes
  • By Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner